AZ starts work on record-setting plant in China

AstraZeneca ($AZN) began construction this week of the corporate-record-setting manufacturing plant in China Medical City, Jiangsu Province, that it announced in October. The company said at the time that the $230 million financial commitment is its largest for a single manufacturing facility.

AZ expects to produce IV and solid dosage form treatments at the new facility. It will produce both its own branded drugs and branded generics, reports Shanghai Daily.

The plant, expected to be completed in late 2013, adds to AZ's manufacturing portfolio in China, according to the report.  Its manufacturing and supply site in Wuxi New District, Jiangsu Province, has been operating since 2001.

The manufacturing capacity for generics aligns with AZ's acquisition in November of privately held generics maker Guangdong Beikang Pharmaceutical.

- see the story

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.